Videos

Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.

The director and founder of the Sleep Centers of Middle Tennessee discussed trends in positive airway pressure adherence that his center’s research has revealed.

The director at AbbVie discussed a number of abstracts presented at AAN 2021 involving atogepant and its phase 3 ADVANCE study.

Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.

The neurologist at University of Utah discussed his research presented at AAN 2021 on telestroke’s accuracy of differentiating between acute ischemic stroke and mimics.

Mindy K. Bixby, DO and Laxman Bahroo, DO compare subcutaneous and sublingual apomorphine hydrochloride and discuss important factors to consider when selecting a formulation.

Experts in the management of Parkinson’s Disease OFF episodes provide insight into the sublingual formulation of apomorphine hydrochloride and discuss differences in its safety and efficacy profiles.

The potential connection between risk of dementia in patients treated with triptans for migraine as compared to the safety profiles of newer CGRP monoclonal antibodies.

Jessica Ailani, MD, of MedStar Health, describes the mechanisms of action and indications for use of currently available CGRP inhibitors for migraine.

The professor of neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford Medicine discussed the ULTIMATE trial data presented at the 2021 AAN Annual Meeting.

The dean at the University of Exeter Medical School discussed the questions related to treating dementia-related psychosis and the options available.

Key opinion leaders ALS care comment on best practices when communicating with patients about the unpredictability of disease progression and prognosis.

Panelists provide insight into what primary care physicians should consider when differentiating amyotrophic lateral sclerosis (ALS) from conditions with similar presentations. 

Leaders in neurology provide insight into first-line disease-modifying therapies for relapsing-remitting multiple sclerosis, such as interferon or glatiramer acetate, and glucocorticoids for acute events.

The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.

The vascular neurology fellow at the University of Maryland Medical Center discussed strategies to improve stroke care efficiency in women and African Americans.

Richard shares his experience receiving his infusion therapy for treatment of multiple sclerosis.

An expert neurologist discusses treatment options for progressive multiple sclerosis.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.

Clyde E. Markowitz, MD, comments on the growing role of magnetic resonance imaging to help diagnose multiple sclerosis and highlights characteristics of lesions he looks at during a diagnostic evaluation.

Patricia K. Coyle, MD, highlights revisions to the McDonald diagnostic criteria for multiple sclerosis and emphasizes why health care professionals need to start referring to the criteria in a more standard fashion.

The chief of neurology at Ascension Saint Agnes discussed how providing an overview of patient-specific risk factors and mitigation can improve poststroke care.

The vascular neurology fellow at the University of Maryland Medical Center discussed findings that African American women had the lowest functional performance in stroke rehabilitation.

The professor of neurology at Mayo Clinic discussed the reasoning for the research he presented at AAN 2021 on social determinants and their impact on epilepsy treatment times.

Neurology News Network for the week ending April 17, 2021.

The chief of neurology at Ascension Saint Agnes discussed her team’s efforts to increase compliance in providing patient-specific stroke DCI.

Episode 9 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the Veterans Health Administration; and Douglas J. Gelb, MD, PhD, of the University of Michigan [WATCH TIME: 5 minutes]

Clinicians elaborate on key trial data revealed through the APOLLO and NEURO-TTR studies in hereditary ATTR amyloidosis.

Treatment overview of hereditary ATTR amyloidosis and considerations for using newer therapies such as patisiran or inotersen in appropriate patients.

A panel of key opinion leaders in neurology considers the importance of newborn screening for spinal muscular atrophy in order to start patients on treatment as early as possible.